1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,320 | 1,820 | 07:51 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Q-LINEA Aktie jetzt für 0€ handeln | |||||
| Fr | Q-Linea AB: Interim report January 1 - June 30 2026 | 834 | GlobeNewswire (Europe) | FDA decision sets up for growth in U.S. FDA clearance for expanded U.S. menu combined with encouraging progress across Europe and focus organisation, positions Q-linea for growth during the second half... ► Artikel lesen | |
| 29.05. | Q-Linea AB: Annika Blondeau Henriksson new interim CFO | 387 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces that the company has hired Annika Blondeau Henriksson as CFO and IR. Annika takes office on June 15, 2026, when she succeeds Christer Samuelsson, who... ► Artikel lesen | |
| 27.05. | Q-linea AB: Bulletin From Annual General Meeting In Q-linea AB (publ) | 310 | GlobeNewswire (Europe) | The annual general meeting of Q-linea AB (publ) (the "Company"), reg. no. 556729-0217, was held on 27 May 2026 in Uppsala, at which the shareholders mainly passed the following resolutions. All resolutions... ► Artikel lesen | |
| 30.04. | Q-Linea AB: Interim report January - March 2026 | 345 | GlobeNewswire (Europe) | Growing recurring income and increased market activity within rapid AST
First quarter: 1 January-31 March 2026Income from sales of consumables amounted to SEK 1.4 (0.9) million, an increase of approx.... ► Artikel lesen | |
| 16.04. | Q-Linea AB: Q-linea announces FDA clearance of expanded ASTar blood testing menu | 546 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces the company has received 510(k) clearance from the US FDA for its expanded ASTar® Gram-negative Blood Culture menu.
The expanded panel represents a significant... ► Artikel lesen | |
| 30.12.25 | Q-Linea AB: Q-linea signs first distribution agreement in South Asia | 468 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA today announces the signing of its first distribution agreement in South Asia, marking an important milestone in the company's global expansion strategy. The agreement... ► Artikel lesen | |
| 23.12.25 | Q-Linea AB: Q-linea announces first two US hospital systems' clinical implementation of ASTar | 248 | GlobeNewswire (Europe) | Q-linea AB (Publ) (OMX: QLINEA) announces the clinical implementation of the first US ASTar instruments at UI (University of Iowa) Health Care and a large healthcare system in Texas. UI Health Care... ► Artikel lesen | |
| 20.11.25 | Q-Linea AB: Q-linea announces new organisation and changes in executive leadership team | 414 | GlobeNewswire (Europe) | Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) today announces that it has reached agreement with all relevant unions regarding the company's new organisation. As part of these changes, Ylva Molin has... ► Artikel lesen | |
| 18.11.25 | Q-Linea AB: Q-linea announces FDA submission for expanded claims for ASTar BC G- panel | 734 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today announces their FDA 510(k) submission for expanded organism and antimicrobial claims on their ASTar BC G- panel, improving the clinical utility of the panel for... ► Artikel lesen | |
| 11.11.25 | Q-Linea AB: Q-linea announces outcome of rights issue | 252 | GlobeNewswire (Europe) | Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA) announces the outcome of the Company's rights issue of approximately SEK 322 (the "Rights Issue"), for which the subscription... ► Artikel lesen | |
| 24.10.25 | Listing of subscription rights and paid subscription shares of Q-Linea AB | 388 | GlobeNewswire | With effect from October 27, 2025, the subscription rights of Q-Linea AB will be traded on the list for Equity rights. Trading will continue up until and including November 05, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 22.10.25 | Q-Linea AB: Q-linea announces cost efficiency program to accelerate sales and marketing activities | 275 | GlobeNewswire (Europe) | Driven by Q-linea's strong commercial progression with a growing customer base, Q-linea today announced a cost efficiency program to optimise the organisation and cost structure to meet the increasing... ► Artikel lesen | |
| 21.10.25 | Q-Linea AB: Bulletin from Extraordinary General Meeting in Q-Linea AB (publ) | 258 | GlobeNewswire (Europe) | The extraordinary general meeting of Q-linea AB (publ) (the "Company"), org.nr. 556729-0217, was held on October 21, 2025 in Uppsala, Sweden, at which the shareholders primarily resolved as follows.... ► Artikel lesen | |
| 21.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.10.2025 | 353 | Xetra Newsboard | Das Instrument 3F80 SE0025420714 Q-LINEA AB EQUITY wird cum Kapitalmassnahme gehandelt am 21.10.2025 und ex Kapitalmassnahme am 22.10.2025 The instrument 3F80 SE0025420714 Q-LINEA AB EQUITY is traded... ► Artikel lesen | |
| 20.10.25 | Q-Linea AB: Interim report 1 January - 30 September 2025 | 275 | GlobeNewswire (Europe) | Strong pipeline growth while the installed base of ASTar increases demand for consumables
The quarter July - September 2025Net sales amounted to SEK 3.5 (0.6) million.Operating result (EBIT) of SEK... ► Artikel lesen | |
| 19.10.25 | Q-Linea AB: Stuart Gander appointed CEO and Anders Ljunggren appointed deputy CEO of Q-linea AB | 266 | GlobeNewswire (Europe) | The board of directors of Q-linea AB (publ) has today appointed Stuart Gander as CEO of the company. Former CEO Anders Ljunggren continues as deputy CEO of the company.
Since March 1, 2024, Stuart Gander... ► Artikel lesen | |
| 03.10.25 | Q-Linea AB: US Trauma Center signs commercial contract | 412 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) announces adoption of the first Accelerate Pheno conversion to the ASTar system by a prominent US level 1 University Hospital Trauma Center.
The University hospital selected... ► Artikel lesen | |
| 18.09.25 | Q-Linea AB: Q-linea | Letter from the CEO | 326 | GlobeNewswire (Europe) | Q-linea AB (publ) (OMX: QLINEA) today shared a Company update.
Key messagesReiterating target of 30 - 40 ASTar units contracted by end of year 2025 with outlook for 100 - 120 by end of 2026 and exceeding... ► Artikel lesen | |
| 18.09.25 | Q-Linea AB: Q-linea resolves to carry out a rights issue of approximately SEK 322 million and announces terms | 395 | GlobeNewswire (Europe) | Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA), announces that the board of directors today has resolved to carry out a share issue of approximately SEK 322 million with preferential... ► Artikel lesen | |
| 05.09.25 | Q-Linea AB: Q-linea to initiate new clinical evaluations of ASTar in the GCC region | 524 | GlobeNewswire (Europe) | Q-linea AB (Publ) (OMX: QLINEA) announces 2 new clinical evaluations of ASTar in Saudi Arabia and Kuwait.
Q-linea, through the distributor partner AMICO Group, is moving into clinical evaluation of... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 42,570 | +0,83 % | DAX nach Rekord tiefer: Börsen-Beben in Südkorea - Bayer, Rheinmetall, Fresenius und Kion ... | Beim deutschen Leitindex zeichnet sich am Dienstag ein schwächerer Start in den Handelstag ab. Schlechte Vorgaben aus Asien belasten den DAX. Während der Nikkei zur Stunde rund zwei Prozent verliert... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,930 | +0,22 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 30,600 | +4,51 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| INTUITIVE SURGICAL | 356,80 | +0,14 % | Intuitive Surgical-Aktie: Dreht die Aktie wieder nach oben? | Die Aktie von Intuitive Surgical zeigt nach den deutlichen Kursverlusten der vergangenen Monate wieder erste Erholungstendenzen. Neben starken Fundamentaldaten sorgen auch positive Analysteneinschätzungen... ► Artikel lesen | |
| DRAEGERWERK | 83,80 | +3,20 % | DRAEGERWERK AG & CO KGAA ST stabil im Kerntrend | ||
| MEDTRONIC | 73,02 | -0,57 % | Medtronic gains on reimbursement hopes for blood pressure therapy | ||
| THERMO FISHER | 458,60 | -0,65 % | Persistence Market Research Pvt. Ltd.: Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG | LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient... ► Artikel lesen | |
| TELADOC HEALTH | 7,912 | -2,73 % | Teladoc (TDOC) Rises Higher Than Market: Key Facts | ||
| HIMS & HERS HEALTH | 29,860 | -0,93 % | Truist reiterates Hold on Hims and Hers stock, $23 target on peptide uncertainty | ||
| SERNOVA BIOTHERAPEUTICS | 0,076 | -4,30 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| DEXCOM | 65,80 | 0,00 % | Here's Why You Should Retain DexCom Stock in Your Portfolio for Now | ||
| ALCON | 59,02 | +0,68 % | RxSight, Inc.: Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs | Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,590 | +0,61 % | PRESSESPIEGEL/Unternehmen: PORSCHE, COMMERZBANK, RHEINMETALL, KNORR-BREMSE, UBER, CONDOR, SIEMENS HEALTHINEERS | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
PORSCHE - Im Zuge seines Sanierungskurses baut der Sportwagenhersteller... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 71,44 | +0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| LIFESTANCE HEALTH GROUP | 10,705 | 0,00 % | LifeStance Health Group, Inc. - 8-K, Current Report |
Q-LINEA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,430 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu Q-LINEA AB finden Sie auf Wallstreet Online.